GABA Therapeutics will be conducting the following Phase 1 studies:

  1. Initially etifoxine will be studied to measure its ability to increase endogenous neurosteroids in man.
  2. Secondly, GRX-917 (deuterated etifoxine) will be studied for toxicology, safety, dosing and its ability to increase endogenous neurosteroids in man.